Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
The purpose of this study is to determine the safety, tolerability and to establish the recommended Phase 2 dose (RP2D) of TAK-981 in combination with rituximab in participants with r/r CD20+ NHL in Phase 1, and to evaluate the efficacy of TAK-981 in combination with rituximab in select r/r CD20+ NHL indications in Phase 2.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society